Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Core Insights - Crescent Biopharma is advancing CR-001, a PD-1 x VEGF bispecific antibody, with promising preclinical data demonstrating its cooperative pharmacology and robust anti-tumor activity, set to be presented at the SITC Annual Meeting [1][2][3] Group 1: Product Development - CR-001 combines two validated mechanisms in oncology by blocking PD-1 and VEGF, enhancing T-cell activation and reducing tumor blood supply [2][4] - Preclinical studies show CR-001's increased binding to PD-1 in the presence of VEGF, leading to enhanced PD-1/PD-L1 signaling blockade [2][4] - The company plans to initiate a global Phase 1 trial for CR-001 in patients with solid tumors in the first quarter of 2026 [3] Group 2: Clinical Data and Efficacy - CR-001 demonstrated potent anti-tumor activity in xenograft mouse models and was well-tolerated in non-human primates after a single intravenous dose [2][4] - The cooperative mechanism of CR-001 is expected to reduce tumor growth in vivo, positioning it as a next-generation immuno-oncology therapy [3] Group 3: Company Vision and Pipeline - Crescent Biopharma aims to build a leading oncology company with a pipeline that includes CR-001 and novel antibody-drug conjugates (ADCs) [5] - The company focuses on leveraging multiple modalities and established targets to advance transformative therapies for solid tumors [5]